Webinar – HLA Genotype Shapes JAK2 V617F Driven Oncogenesis

21/09/2020

Join us for a webinar with Prof. Milena Ivanova MD (Molecular Biologist, Lab Co-Director at the Dept. of Clinical Immunology, University Hospital Aleksandrovska, Sofia, Bulgaria) and Libor Kolesár (Senior Field Applications Scientist & Assay Product Manager, Omixon). HLA class I and class II alleles have been shown to be...

Loss of Heterozygosity – “Cancer Mimicry”

27/06/2019

Article written by Vera Siffnerova (FAS, Omixon) In most Slavic languages, LOH stands for Summer Olympic Games (e. g. Letní Olympijské Hry in Czech), in HLA world, LOH is known as an abbreviation of an important disease marker – Loss of Heterozygosity – during which different types of cancer cells...

How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

15/12/2017

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017 While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA genotyping....

Human Leukocyte Antigen as a Critical Biomarker for the Adoption of Novel Immunotherapies of Cancer

15/06/2017

– Written by Attila Bérces (Founder and Chairman, Omixon) While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation is still the dominant driver for the clinical HLA typing market. A new therapeutic paradigm in cancer immunotherapy...

Cancer Immunotherapy Proved to be Fertile Ground for Personalized Medicine

14/09/2016

Written by Dr. Attila Berces, Chairman at Omixon. Share the original article on LinkedIn here… “We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered...